Physicians' Academy for Cardiovascular Education
In a post-hoc analysis of the AFIRE trial, rivaroxaban monotherapy was associated with a 38% lower risk of first and subsequent thrombotic and bleeding events in patients with AF and stable coronary artery disease compared with combination therapy of rivaroxaban with antiplatelet agents.
ATTR-CM is a progressive, often fatal form of cardiac disease characterized by accumulation of transthyretin in the heart. It is unclear how often thromboembolic complications occur in patients with ATTR-CM.
Prof. Marx and Prof. Lehrke discuss a case of a 64-year old patient with T2DM and acute MI. What are the treatment options in this patient?
In a community-based cohort study on hypertrophic cardiomyopathy (HCM), few patients died each year of the disease but HCM-related morbidity was substantial.
The American Diabetes Association (ADA) has made important updates to the Standard of Medical Care in Diabetes 2022. Updates include new data on finerenone in T2DM and CKD, SGLT2i in T2DM and calculating eGFR.
Managing hyperkalemia while optimizing RAASi therapy in patients with heart failure can be challenging. Andrew Coats talks about this clinical dilemma.
Prof. McMurray talks about barriers and concerns regarding initiating guideline recommended therapy in patients with heart failure.
Ileana Piña, Javed Butler, Marco Metra and Giuseppe Rosano talk about ESC/HFA guideline updates, management strategies for recurrent hyperkalemia, and foundational therapy for patients with heart failure.
Hyperkalemia frequently leads to the interruption or discontinuation of treatment with RAAS inhibitors, which may worsen the prognosis of patients with HF. The SGLT2 inhibitor empagliflozin may offer relief here.
In a large cohort of AF patients, new brain infarcts occurred frequently, despite a high anticoagulation rate. Both clinically overt and silent brain infarcts were associated with cognitive decline.
EAS 2022 "According to [these] data, there is no reason why you should give aspirin to an individual with high Lp(a)," says prof. Catapano. He recapitulates the findings of a study by Olmastroni and colleagues.
EAS 2022 Kanika Dharmayat talks about how to achieve early identification of FH patients based on findings from an analysis of the EAS FHSC global registry on children and adolescents with FH.
